{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:41:10Z","timestamp":1771350070371,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bpobgyn.2022.01.013","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T01:27:40Z","timestamp":1644974860000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Gynecological management of the breast cancer survivor"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0447-5823","authenticated-orcid":false,"given":"Mary Kathryn","family":"Abel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamandra","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Othieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2022.01.013_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib3","series-title":"WHO model list of essential medicines - 22nd list","year":"2021"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib5","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ajog.2004.12.083","article-title":"Benign gynecologic conditions among participants in the breast cancer prevention trial","volume":"192","author":"Chalas","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/OGX.0b013e3181a713f1","article-title":"Women's health, breast health: a review of the gynecologic effects of breast cancer","volume":"64","author":"Goldman","year":"2009","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-016-3874-0","article-title":"Weight gain during adjuvant endocrine treatment for early-stage breast cancer: what is the evidence?","volume":"158","author":"Nyrop","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/IGC.0b013e3181a47cbe","article-title":"Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients","volume":"19","author":"Buijs","year":"2009","journal-title":"Int J Gynecol Cancer: Official Journal of the International Gynecological Cancer Society"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","article-title":"Endometrial pathologies associated with postmenopausal tamoxifen treatment","volume":"94","author":"Cohen","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/bjs.10899","article-title":"Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy","volume":"105","author":"Fleming","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib11","first-page":"222","article-title":"The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen. Medical Principles and Practice","volume":"19","author":"Kazerooni","year":"2010","journal-title":"Int J Kuwait University, Health Science Centre"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ygyno.2004.06.033","article-title":"The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients","volume":"94","author":"Markovitch","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/AOG.0b013e31824e12ce","article-title":"126: management of gynecologic issues in women with breast cancer","volume":"119","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.01.013_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165625","article-title":"Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects","volume":"21","author":"Tenti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"van Poznak","year":"2010","journal-title":"J\u00a0Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-019-0339-1","article-title":"Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis","volume":"20","author":"He","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-017-4627-4","article-title":"Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis","volume":"168","author":"Underwood","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3109\/0284186X.2016.1155738","article-title":"Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis","volume":"55","author":"Zavos","year":"2016","journal-title":"Acta Oncol (Stockh)"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1089\/jwh.2015.5194","article-title":"Understanding fertility in young female cancer patients","volume":"24","author":"Waimey","year":"2015","journal-title":"J\u00a0Wom Health"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/1744666X.2020.1724091","article-title":"A\u00a0systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease","volume":"16","author":"Luong","year":"2020","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib23","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/humrep\/dev060","article-title":"Ovarian reserve after treatment with alkylating agents during childhood","volume":"30","author":"Thomas-Teinturier","year":"2015","journal-title":"Hum Reprod (Oxf)"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-009-0401-6","article-title":"The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review","volume":"116","author":"Peate","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.24835","article-title":"The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer","volume":"116","author":"Abusief","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib26","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J\u00a0Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.01.013_bib27","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.26403","article-title":"Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer","volume":"118","author":"Letourneau","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1530\/EC-18-0180","article-title":"Post-chemotherapy serum anti-M\u00fcllerian hormone level predicts ovarian function recovery","volume":"7","author":"Kim","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2013.52.8877","article-title":"Prospective study of fertility concerns and preservation strategies in young women with breast cancer","volume":"32","author":"Ruddy","year":"2014","journal-title":"J\u00a0Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib30","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.contraception.2014.01.014","article-title":"Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk","volume":"89","author":"Quinn","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1634\/theoncologist.2011-0121","article-title":"Use of tamoxifen before and during pregnancy","volume":"16","author":"Braems","year":"2011","journal-title":"Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib33","first-page":"CD007245","article-title":"Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen","volume":"2015","author":"Dominick","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2012.05.008","article-title":"Cancer and contraception","volume":"86","author":"Patel","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112506","article-title":"Estrogens and progestogens in triple negative breast cancer: do they harm?","volume":"13","author":"van Barele","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib36","first-page":"1","article-title":"U.S. Medical eligibility Criteria for contraceptive use","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep) : MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib37","first-page":"74","volume":"vol. 47","author":"Azim","year":"2011"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamaoncol.2017.0248","article-title":"Association of the timing of pregnancy with survival in women with breast cancer","volume":"3","author":"Iqbal","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000501473","article-title":"Tamoxifen exposure during pregnancy: a systematic review and three more cases","volume":"15","author":"Buonomo","year":"2020","journal-title":"Breast Care"},{"issue":"15","key":"10.1016\/j.bpobgyn.2022.01.013_bib40","article-title":"Positive (IBCSG 48-14\/BIG 8-13\/A221405): evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy","author":"Partridge","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib41","first-page":"CD013538","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib42","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic\/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.2.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 9, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib43","first-page":"1183","article-title":"Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors","volume":"29","author":"Tran","year":"2021","journal-title":"Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib44","first-page":"4243175","article-title":"Nonhormonal hot flash management for breast cancer survivors: a systematic review and network meta-analysis. Evidence-based complementary and alternative medicine","volume":"2020","author":"Liu","year":"2020","journal-title":"ECAM"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib45","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/cncr.29194","article-title":"Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial","volume":"121","author":"Bower","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib46","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.2016.8012","article-title":"Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis","volume":"315","author":"Franco","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib47","first-page":"CD007244","article-title":"Black cohosh (Cimicifuga spp.) for menopausal symptoms","volume":"2012","author":"Leach","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13697137.2020.1820477","article-title":"Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence","volume":"24","author":"Castelo-Branco","year":"2021","journal-title":"Climacteric: The Journal of the International Menopause Society"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib49","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NCCN Guidelines Insights: Survivorship V.1.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 9, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib50","doi-asserted-by":"crossref","first-page":"101469","DOI":"10.1016\/j.smrv.2021.101469","article-title":"Pharmacologic and hormonal treatments for menopausal sleep disturbances: a network meta-analysis of 43 randomized controlled trials and 32,271 menopausal women","volume":"57","author":"Cheng","year":"2021","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib52","first-page":"52","volume":"vol. 49","author":"Fahl\u00e9n","year":"1990-2013"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib54","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/AOG.0000000000001349","article-title":"Committee opinion number 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer","volume":"127","author":"American College of Obstetricians and Gynecologists","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"Journal of Oncology Practice"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib58","first-page":"1335","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib59","series-title":"FDA warns against use of energy-based devices to perform vaginal \u201crejuvenation\u201d or vaginal cosmetic procedures: FDA safety communication","year":"2018"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib60","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2021.14892","article-title":"Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial","volume":"326","author":"Li","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1758834016687260","article-title":"A\u00a0clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy","volume":"9","author":"Sousa","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib62","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A\u00a0practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib63","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0897190016630409","article-title":"Flibanserin: a novel, nonhormonal agent for the treatment of hypoactive sexual desire disorder in premenopausal women","volume":"30","author":"Vallejos","year":"2017","journal-title":"J\u00a0Pharm Pract"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000134","article-title":"Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib65","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1060028019899152","article-title":"Bremelanotide: new drug approved for treating hypoactive sexual desire disorder","volume":"54","author":"Mayer","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib66","unstructured":"American Association of Sexuality Educators, Counselors and therapists. https:\/\/www.aasect.org\/. Accessed January 18, 2021."},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib67","unstructured":"Breast cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer (accessed January 19, 2022)."},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib68","series-title":"Cancer facts & figures","year":"2021"},{"key":"10.1016\/j.bpobgyn.2022.01.013_bib69","unstructured":"Reproduced with permission from the NCCN Guidelines Survivorship Version 1.2022. \u00a9 2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:13:47Z","timestamp":1761498827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693422000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":69,"alternative-id":["S1521693422000220"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.01.013","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gynecological management of the breast cancer survivor","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}